Conditional Marketing Authorisation Application submitted for Novavax's COVID-19 Vaccine Nuvaxovid
Novavax CZ AS has submitted a conditional marketing authorisation application to the European Medicines Agency (EMA) for its COVID-19 vaccine candidate Nuvaxovid. The previous rolling review process had started for the vaccine on 03.02.2021: Since then, the successively submitted data have been continuously evaluated by the experts of the national medicinal product authorities in Europe at the EMA. The Committee for Medicinal Products for Human Use (CHMP) is expected to decide on a possible recommendation for marketing authorisation by the European Commission in a few weeks.
The COVID-19 vaccine Nuvaxovid (NVX-CoV2373), unlike the previously authorised vaccines against COVID-19, is neither an mRNA nor a vector vaccine: it is a protein-based vaccine and consists of virus-like particles (VLP) containing the spike protein of SARS-CoV-2. Like the other vaccines, Nuvaxovid is expected to protect against COVID-19.